BMC Infectious Diseases · 2014 · 46 citations · 32 references
PharmacyPharmacotherapyHepatitis PharmacotherapyInfectious Disease PharmacotherapyMolecular VirologyAntiviral PharmacotherapyAntiviral TherapyInterferon-based TherapyNucleos(t)ide Analog TherapyViral HepatitisViral Hepatitis TreatmentAntiviral Therapy DiscontinuationChronic Viral HepatitisHepatitis B TherapyPost-treatment RelapseRelapse After TreatmentRelapse IncidenceSeroconversion RatesVirologic Relapse
BACKGROUND: The durability of off-treatment virologic responses has not been fully elucidated in chronic hepatitis B (CHB) patients who have previously achieved complete virologic suppression with nucleos(t)ide analog (NA) therapy. This study aimed to assess off-treatment virologic relapse rates and to characterize the outcomes of subsequent re-treatment in CHB patients who have discontinued oral NA following complete virologic suppression. METHODS: Ninety-five CHB patients who showed complete virologic suppression were withdrawn from NAs: entecavir, lamivudine, and clevudine in 67, 15, and 13 patients, respectively. Consolidation therapy was given for 6 and 12 months for HBeAg-positive and -negative CHB, respectively, before cessation. Virologic relapse was managed with the same NA that had induced complete virologic response before discontinuation. RESULTS: The cumulative rates of virologic relapse at 12 and 24 months were 73.8% and 87.1%, respectively. The relapse rates were independent of HBeAg positivity, HBeAg seroconversion, and type of oral NA. In a multivariate analysis, duration of oral NA therapy was the only significant predicting factor associated with off-treatment virologic relapse. Although the majority of patients regained complete virologic suppression, some patients did not respond to re-treatment with the initial NA and developed genotypic resistance. CONCLUSIONS: NA consolidation therapy for 6 and 12 months is associated with high off-treatment virologic relapse in HBeAg-positive and -negative CHB patients, respectively. Drugs with high genetic barriers to resistance should be considered as a rescue therapy for off-treatment relapse in CHB.
32
Chronic hepatitis B: Update 2009 #
Anna S. Lok, Brian J. McMahon · Hepatology · 2009 · 2.8K citations · Full text
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Yun‐Fan Liaw, Joseph J.�Y. Sung, Wan Cheng Chow et al. · New England Journal of Medicine · 2004 · 2.3K citations · Full text
EASL clinical practice guidelines management of chronic hepatitis B
张学武, Xu Li · Inter J Epidemiol Infect Dis · 2009 · 1.5K citations